I-Mab

NASDAQ:IMABUnited States

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Contact Information

Headquarters

Suite 400, 2440 Research BlvdROCKVILLE, MD, United States 20850

Phone

301-670-2800

Fax

---

Executives

Interim Independent Chairman of the Board

Pamela Klein

Chief Executive Officer, Director

Rajkumar Kannan

Chief Financial Officer

Joseph Skelton

Chief Medical Officer

Phillip Dennis

Chief Medical Officer

John Hayslip